Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, NCI/NIH, Bethesda, Rockville, MD, USA.
Department of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital, Kuching, Sarawak, Malaysia.
Breast Cancer Res Treat. 2017 Oct;165(3):687-697. doi: 10.1007/s10549-017-4356-8. Epub 2017 Jun 29.
To characterize the spectrum of germline mutations in BRCA1, BRCA2, and PALB2 in population-based unselected breast cancer cases in an Asian population.
Germline DNA from 467 breast cancer patients in Sarawak General Hospital, Malaysia, where 93% of the breast cancer patients in Sarawak are treated, was sequenced for the entire coding region of BRCA1; BRCA2; PALB2; Exons 6, 7, and 8 of TP53; and Exons 7 and 8 of PTEN. Pathogenic variants included known pathogenic variants in ClinVar, loss of function variants, and variants that disrupt splice site.
We found 27 pathogenic variants (11 BRCA1, 10 BRCA2, 4 PALB2, and 2 TP53) in 34 patients, which gave a prevalence of germline mutations of 2.8, 3.23, and 0.86% for BRCA1, BRCA2, and PALB2, respectively. Compared to mutation non-carriers, BRCA1 mutation carriers were more likely to have an earlier age at onset, triple-negative subtype, and lower body mass index, whereas BRCA2 mutation carriers were more likely to have a positive family history. Mutation carrier cases had worse survival compared to non-carriers; however, the association was mostly driven by stage and tumor subtype. We also identified 19 variants of unknown significance, and some of them were predicted to alter splicing or transcription factor binding sites.
Our data provide insight into the genetics of breast cancer in this understudied group and suggest the need for modifying genetic testing guidelines for this population with a much younger age at diagnosis and more limited resources compared with Caucasian populations.
在马来西亚砂拉越综合医院的一个基于人群的未经选择的乳腺癌病例中,对 BRCA1、BRCA2 和 PALB2 的种系突变谱进行特征分析,该医院是砂拉越 93%的乳腺癌患者的治疗医院。
对来自马来西亚砂拉越综合医院的 467 名乳腺癌患者的种系 DNA 进行了测序,这些患者全部来自于马来西亚砂拉越,该医院是砂拉越 93%的乳腺癌患者的治疗医院,测序内容包括 BRCA1 的整个编码区;BRCA2;PALB2;TP53 的外显子 6、7 和 8;以及 PTEN 的外显子 7 和 8。致病性变异包括 ClinVar 中的已知致病性变异、功能丧失性变异和破坏剪接位点的变异。
我们在 34 名患者中发现了 27 种致病性变异(11 种 BRCA1、10 种 BRCA2、4 种 PALB2 和 2 种 TP53),BRCA1、BRCA2 和 PALB2 的种系突变患病率分别为 2.8%、3.23%和 0.86%。与非突变携带者相比,BRCA1 突变携带者的发病年龄更早,三阴性亚型更多,体重指数更低,而 BRCA2 突变携带者的阳性家族史更多。与非携带者相比,突变携带者的生存情况更差;然而,这种关联主要是由分期和肿瘤亚型驱动的。我们还发现了 19 种意义不明的变异,其中一些预测会改变剪接或转录因子结合位点。
我们的数据提供了对这一研究较少的人群中乳腺癌遗传学的深入了解,并表明需要修改针对该人群的基因检测指南,因为与白种人群相比,该人群的诊断年龄更小,资源更有限。